File this under “Been down so long, looks like up to me.”

Just 43 percent of patient groups thought the pharmaceutical industry had an “excellent” or “good” reputation last year. Despite the poor showing, however, this is still an improvement — albeit, a modest one — from the 38 percent of patient groups that offered the same assessment in 2016, according to PatientView, a research firm that canvassed more than 1,300 patient groups from 95 countries.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It was my intention to say that our scribe tried rather hard to find a positive side to these bleak numbers. Now that I have converted the intention into words, adieu!

  • Well, 38% “excellent” or “good” may be a “poor showing” for drug companies, but it’s no doubt much higher than the rating for journalists.

    • Hi James,

      Thanks for stopping by.

      The report was not an effort undertaken by STAT, but a research firm, as noted in the post. And the survey collected what patient groups think about those few dozen companies.

      I can understand your frustration, but I believe you’re shooting the messenger.

      Regards
      ed at Pharmalot

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy